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Human T-cell leukemia virus type-1 (HTLV-1) encodes a mitochondrial protein named p13. p13
mediates an inward K+ current in isolated mitochondria that leads to mitochondrial swelling, depo-
larization, increased respiratory chain activity and reactive oxygen species (ROS) production. These
effects trigger the opening of the permeability transition pore and are dependent on the presence of
K+ and on the amphipathic alpha helical domain of p13. In the context of cells, p13 acts as a sensi-
tizer to selected apoptotic stimuli. Although it is not known whether p13 inﬂuences the activity of
endogenous K+ channels or forms a channel itself, it shares some structural and functional analogies
with viroporins, a class of small integral membrane proteins that form pores and alter membrane
permeability.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction activating the viral promoter, affects the expression and function ofHuman T-cell leukemia virus type 1 (HTLV-1) infects about 15–
25 million people worldwide, with high prevalence in southwest-
ern Japan, central Africa and the Caribbean basin. While most in-
fected individuals remain asymptomatic, about 3% eventually
develop an aggressive neoplasm of mature CD4+ cells termed adult
T-cell leukemia/lymphoma (ATLL) that arises after several decades
of infection. HTLV-1 also causes a neurological disease termed
tropical spastic paraparesis/HTLV-associated myelopathy (TSP/
HAM), a progressive demyelinating disease; similar to ATLL, TSP/
HAM arises in about 3% of infected individuals, but after a latency
period of years rather than decades [1].
The 30 portion of the HTLV-1 genome (termed the X region) con-
tains at least four open reading frames (ORFs x-I, II, III and IV) that
code for non-structural regulatory proteins. Expression of these
partially overlapping ORFs is accessed through alternative splicing
and multicistronic translation. Proteins coded in the X region play
key roles in the control of viral gene expression and host cell turn-
over [2]. The ability of HTLV-1 to immortalize T-cells is attributable
primarily to the X-region protein Tax, which, in addition to trans-chemical Societies. Published by E
Scienze Oncologiche e Chir-
5128 Padova, Italy. Fax: +39cellular genes controlling signal transduction, cell growth, apopto-
sis and chromosomal stability [1].2. Amino acid sequence and structural features of HTLV-1 p13
The present review focuses on p13, an 87-amino acid mitochon-
drial protein coded by the HTLV-1 x-II ORF from a singly spliced
mRNA [2–4]. Fig. 1 shows the amino acid sequence (Panel A) and
in silico analysis of p13’s structure (Panel B, ProtScale software,
[5]) indicating that the N-terminus of the protein includes an
amphipathic a-helix (residues 20–35) and a transmembrane re-
gion (residues 30–40). These predictions are supported by circular
dichroism analysis of a synthetic peptide corresponding to residues
9–41 (p139–41) which folds into an a-helix when exposed to mem-
brane-like environments (e.g. SDS and lipid vesicles) [6]. Interest-
ingly, this region contains the mitochondrial targeting signal of
p13 and is essential for its function (see below; [7]). Biochemical
fractionation studies showed that p13 is indeed inserted as integral
membrane protein in the inner mitochondrial membrane (see
below; [6]). The high ﬂexibility score of the PPTSSRP motif
(residues 42–48) suggests that this might represent a hinge region.
The C-terminal region (residues 65–75) is predicted to fold as
a b-sheet structure. This region includes the sequence
WTRYQLSSTVPYPS, which is highly homologous to the syntheticlsevier B.V. All rights reserved.
Fig. 1. p13 sequence and predicted structure. Panel A shows the amino acid sequence of p13 with the mitochondrial targeting signal underlined. Panel B shows in silico
analysis of p13’s structure using the ProtScale Software provided by the ExPASy Proteomics Server; graphs show the predicted scores for a-helix (Deleage & Roux), the
transmembrane tendency, average ﬂexibility, and total beta strand of the different regions of the protein. Panel C shows a hypothetical model of p13’s structure in the context
of the inner mitochondrial membrane based on results of experimental data described in Ref. [6] and in silico predictions shown in Panel B. Segments A–D of the protein
represent, respectively, the amphipathic a-helical domain, the transmembrane domain, the hinge region and the C-terminal beta sheet hairpin. Panel C also shows a more
detailed helical wheel model of the amphipathic a-helical domain of p13 (amino acids 20–35). Panel C does not indicate the matrix and intermembrane space faces of the
inner membrane, as the topology of p13 has not been deﬁned.
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high afﬁnity to a-bungarotoxin, a snake-venom neurotoxin that
inhibits the nicotinic acetylcholine receptor (AChR) at the neuro-muscular junction [8]. Binding of the WRYYESSLEPYPD peptide to
the toxin inhibits the latter’s ability to interact with AChR. NMR
spectroscopy showed that the bound peptide folds into a b-hairpin
Fig. 2. Effects of p13 function at the mitochondrial level: a working model. p13 is
inserted in the inner mitochondrial membrane (IM) and generates an inward K+
current in mitochondria. This effect may result either from the direct channel-
forming ability of p13 (upper part of the scheme) or by its inﬂuence on cellular K+
channels located in the mitochondria (lower part of the scheme). This effect leads to
IM depolarization that in turn increases the activity of the electron transport chain
(ETC) which, by increasing H+ extrusion, dampens the depolarizing effect of p13.
Furthermore, increased ETC activity results in increased ROS production which,
along with membrane depolarization, may lower the opening threshold of the
permeability transition pore (PTP).
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with a triple-stranded b-sheet of the toxin to form a ﬁve-stranded,
antiparallel b-sheet structure. The sequence similarity between
this peptide and residues 65–75 of p13 suggests that the latter
might represent an important protein–protein interaction domain.
Finally, the C-terminal tail of p13 is characterized by several PXXP
motifs that might mediate binding of p13 to proteins containing
SH3 domains. Results of experimental data described in Ref. [6]
and the in silico predictions were integrated to construct a hypo-
thetical model of p13 structure in the context of the inner mito-
chondrial membrane, shown in Fig. 1C.
3. Intracellular localization of p13
Initially p13 was reported to localize to the nucleus [9],
although subsequent studies showed that the protein is mainly tar-
geted to mitochondria [7], with partial nuclear targeting observed
only at higher expression levels. Immuno-electron microscopy and
sub-mitochondrial fractionation experiments demonstrated that
the majority of p13 is inserted as an integral membrane protein
in the inner mitochondrial membrane [6]. The mitochondrial tar-
geting of p13 is directed by an atypical mitochondrial targeting se-
quence (MTS) formed by 10 amino-proximal residues (amino acids
21–30) that are contained within the a-helix described above [7],
with four arginines in the MTS conferring amphipathic properties
to the helix. In contrast to canonic MTSs, the targeting signal of
p13 is not cleaved upon import into mitochondria [7]. More re-
cently Ghorbel et al. [10] described a nuclear localization sequence
(NLS) at the C-terminus of p13. The authors suggest that this NLS
may target p13 to the nucleus in conditions in which the MTS is
masked.
4. Effects of p13 on mitochondria
In the context of cells, p13 expression was shown to induce
mitochondrial fragmentation [7]. This effect is dependent on the
presence of positively charged amino acids in the MTS. Interest-
ingly, these residues are not essential for mitochondrial targeting
of p13 [6], suggesting that the mitochondrial targeting and mito-
chondrial-fragmenting functions mediated by the amphipathic
a-helix might be somewhat distinct. To deﬁne the mechanism of
function of p13 at the mitochondrial level, we carried out experi-
ments using isolated rat liver mitochondria and synthetic p13.
Assays were carried out in isotonic K+ buffer and mitochondria
were energized with glutamate and malate. In these experimental
conditions p13 induced osmotic swelling of mitochondria mea-
sured as 90 light scattering at 540 nm. Using a rhodamine 123
dequenching assay we also showed that p13 alters inner mito-
chondrial membrane potential (Dw). This effect is tightly linked
to the ability of the protein to change K+ permeability, as mutants
unable to induce K+-dependent swelling also did not inﬂuence Dw.
Similar results were obtained with the shorter p13 peptide
(p139–41) [6], although the full-length protein is about 10-fold
more potent than p139–41. The effects induced by p13 are dose-
dependent, and at low p13 concentrations swelling is reverted by
mitochondrial depolarization (e.g. by using protonophores).
‘‘Reversible” swelling induced by low doses of p13 is not accompa-
nied by mitochondrial depolarization or cytochrome c release; in
contrast, higher concentrations of p13 induce irreversible swelling,
depolarization and cytochrome c release from isolated mitochon-
dria [11]. p13 induces a shape change in mitochondria, which
acquire a crescent-like morphology that is distinct from that
resulting from large-amplitude swelling triggered by opening of
the permeability transition pore (PTP), a large conductance mito-
chondrial channel controlling cytochrome c release and apoptosis[11]. Interestingly, these shape changes are evident at low doses
of p13 (e.g. 50 nM) and are is reverted by depolarization induced
by protonophores, suggesting that the basis for this change is di-
rectly linked to energy-dependent K+ inﬂux. Irreversible swelling
triggered by high doses of p13 results in a change in mitochondrial
morphology that resembles that induced by PTP opening (i.e. large-
amplitude swelling with loss of internal electron-dense structure).
The effects of p13 on mitochondrial respiration were tested by
polarographic measurements of O2 consumption with a Clark oxy-
gen electrode. Results showed that p13 triggers a dose-dependent
increase in mitochondrial respiration; interestingly, this change, by
extruding H+ from the matrix, maintains Dw at least within a low
concentration range of p13 [11]. These changes lead to increased
mitochondrial ROS production, which was measured using the
ﬂuorescent H2O2 probe Amplex UltraRed in the presence of horse-
radish peroxidase [11]. The Increased ROS production and depolar-
ization induced by p13 in turn lower the opening threshold of the
PTP [11], which was assessed using the calcium retention capacity
assay based on the Ca2+ ﬂuorescent probe Calcium Green-5N [12].
One of the questions left unanswered by the studies carried out
thus far is whether the effects of p13 on mitochondrial permeabil-
ity result from its interaction with an endogenous mitochondrial
channel [13] or, in alternative, if p13 exhibits intrinsic channel-
forming activity (Fig. 2). Searches for binding partners of p13 based
on yeast 2-hybrid screens and pull-down assays indicate that p13
binds to a protein of the nucleoside monophosphate kinase super-
family, actin-binding protein 280, and farnesyl pyrophosphate syn-
thase [14,15], none of which would be expected to form part of a K+
channel. On the other hand, p13 displays several properties that
indicate that it might form channels itself, including its insertion
into membranes, the presence of the amphipathic a-helix and a
transmembrane domain mentioned above and its propensity to
form high-order, SDS-resistant complexes ([6]; Silic-Benussi,
unpublished observations). This latter characteristic is a hallmark
of proteins that assemble into transmembrane oligomeric a-helical
bundles such as viroporins ([16], see below).
5. Effects of p13 on cell turnover and transformation
Expression of p13 in HeLa cells and Jurkat T-cells results in
reduced proliferation rates and increased sensitivity to apoptosis
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tent with the hypothesis that p13 may act by lowering the thresh-
old of PTP opening, as observed in isolated mitochondria.
Furthermore, p13 was recently conﬁrmed to affect ROS production
when expressed in cells (Silic-Benussi et al., unpublished
observations).
Mitochondria play a pivotal role in the control of intracellular
Ca2+ homeostasis [reviewed by [19]]. As p13 affects mitochondrial
Dw, the driving force of mitochondrial Ca2+ uptake, we also asked
whether the protein affects calcium homeostasis. Consistent with
this hypothesis, p13 increases phosphorylation of the CREB tran-
scription factor on serine 133 in response to histamine [18], an
event that is mediated by the Ca2+-dependent activation of CAM ki-
nase. These data are supported by recent studies that showed that
p13 alters mitochondrial Dw and Ca2+ uptake in the context of liv-
ing cells (Biasiotto et al., unpublished observations). In analogy
with other properties described for p13, these effects depend on
the protein’s amphipathic a-helical domain. These ﬁndings rein-
force the idea that p13 may play an important role in controlling
cell signalling, activation and proliferation.
The properties described for p13 are of interest in the general
context of tumour virology, as all of the human tumour viruses ex-
press at least one mitochondrial protein, some of which alter mito-
chondrial ion permeability and/or membrane potential, either
through direct channel-forming activity or through interactions
with endogenous channels. Consistent with the central role of
mitochondria in energy production, cell death, calcium homeosta-
sis, and redox potential, these proteins have profound effects on
host cell physiology [3].6. Mitochondrial K+ channels and cell turnover
The possibility that p13 might control cell turnover by affecting
mitochondrial K+ permeability and ROS production is also consis-
tent with the fact that mitochondrial ATP-sensitive potassium (mi-
toKATP) channels are involved in controlling cell survival and death
[20]. mitoKATP channels are, in fact, strongly implicated in the pro-
tection from apoptosis that characterizes ischemic preconditioning
in the heart. Although the molecular composition of mitoKATP
channels is still elusive, recent ﬁndings suggest that mitoKATP
may be functionally connected to the PTP and inﬂuence apoptosis
induced through PTP opening [21]. These ﬁndings are consistent
with results of a study demonstrating that p13 signiﬁcantly inhib-
ited the growth of experimental tumors in vivo [18].7. Viral channel proteins: functional comparison of p13 with
viroporins
A growing number of animal viruses have been shown to en-
code ‘‘viroporins”, a class of small hydrophobic integral membrane
proteins characterized by at least one amphipathic a-helix [16].
Upon membrane insertion, viroporins oligomerize and assemble
into pores that control membrane permeability (reviewed in
[16]). The properties of viroporins suggest that they might repre-
sent ancestors of more complex cellular channels in which the pore
is formed by a bundle of transmembrane helixes contained in a sin-
gle protein rather than by a multimeric bundle of separate
proteins.
Although direct channel activity of HTLV-1 p13 has not yet been
investigated, its structure and effects on membrane K+ permeabil-
ity (see above) suggest that it may act as a viroporin. In general,
viroporins described so far act at two main levels: (i) enhancement
of virion morphogenesis, by promoting viral entry and/or release of
viral particles and (ii) control of host cell apoptosis. The ability of
p13 to inﬂuence the response of cells to apoptotic stimuli suggeststhat it might fall into the second category of viroporins, along with
PB1-F2 protein of Inﬂuenza A virus (IAV), 2B protein of poliovirus
and Vpr of the human immunodeﬁciency virus (HIV-1). Indeed,
an increasing number of animal viruses have been shown to trigger
apoptosis in infected cells at late stages of infection [22], examples
include poliovirus and coxsackievirus [23,24], alphaviruses, coro-
naviruses, inﬂuenza viruses and HCV [25–28].
The PB1-F2 protein of Inﬂuenza A virus (IAV) is encoded by an
alternative reading frame of the PB1 polymerase gene. PB1-F2
localizes in the nucleus, cytosol and mitochondria of infected cells.
PB1-F2 is conserved in most mammalian and avian IAV isolates as
a 78–90 amino acid protein, while it is not present in the inﬂuenza
B virus strains [29]. PB1-F2 contains an amphipathic helix span-
ning residues 69–83, is targeted to mitochondria and triggers cell
death, all features which are reminiscent of HTLV-1 p13 [29].
Although the function(s) of PB1-F2 in IAV biology are not fully elu-
cidated at present, the fact that the protein induces apoptosis in
human monocytes [30,31] suggests that it might play a role in
inhibiting the immune response towards IAV-infected cells [29].
Although PB1-F2 is not essential for viral replication in vitro, it in-
creases viral pathogenicity in mice [32,33]. Interestingly, a single
amino acid mutation in PB1-F2 (asparagine 66 to serine) is sufﬁ-
cient to confer a highly pathogenic phenotype to IAV [34,35]. Fur-
thermore, PB1-F2 coded by the IAV that caused the 1918 inﬂuenza
pandemic was shown to enhance secondary bacterial pneumonia
[36], a major cause of death in IAV-infected individuals. More re-
cently it was shown that phosphorylation of PB1-F2 by protein ki-
nase C is essential for the apoptosis-promoting activity of PB1-F2
in monocytes [37]. This ﬁnding suggests that the activity of PB1-
F2 might be controlled through the engagement of speciﬁc signal
transduction pathways.
In analogy to other viroporins, the non-structural 2B protein of
poliovirus contains a lysine-rich amphipathic domain that is con-
served among 2B homologues of other members of the Picornavir-
idae family [38,39]. This protein exhibits pore-forming activity that
was mapped to a small amphipathic region which permeabilizes
the plasma membrane to small solutes [40]. The 2B protein is also
partially localized to mitochondria, alters mitochondrial mem-
brane permeability and morphology, triggers cytochrome c release
and caspase-3 activation and induces apoptosis through the mito-
chondrial pathway. The observations made for 2B suggest that the
pro-apoptotic activity of some viroporins may depend on their
translocation to mitochondria and permeabilization of mitochon-
drial membranes [41]. The pore-forming domain of 2B was also
shown to translocate across the plasma membrane [40], an effect
that might be linked to its pore-forming activity.
Human immunodeﬁciency virus-1 (HIV-1) Vpr is a 14-kDa mul-
tifunctional protein that is detected in the nucleus, mitochondria,
and in mature viral particles. Vpr contains three a-helices (amino
acids 17–33, 38–50 and 56–77) surrounded by ﬂexible N- and C-
terminal domains, and folded around a hydrophobic core [42].
Exposure of isolated mitochondria or intact cells to Vpr results in
mitochondrial depolarization and release of pro-apoptotic proteins
from mitochondria [43]. Induction of cell death and the permeabil-
ity transition are dependent on a region of Vpr which includes the
third a-helix and critical arginine residues (amino acids 52–96);
both effects are blocked by BCL-2 and PTP inhibitors. Experiments
carried out using ANT- or VDAC-defective yeast strains showed
that Vpr-induced cell death is dependent on these proteins, which
were proposed to be associated with the PTP [43]. In vitro studies
showed that Vpr binds to ANT and form channels with it in artiﬁ-
cial membranes. Interestingly, BCL-2 is able to interfere with the
Vpr-ANT interaction and with Vpr’s pore-forming activity [44]. In
addition to these effects, Vpr mediates nuclear targeting of the vir-
al genome [45], although this activity has been challenged by more
recent studies [46]. Furthermore, Vpr induces cell cycle arrest at
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complex [47–49]. The fact that HIV-1 viral production is upregu-
lated in G2 [48] suggests that Vpr might increase viral replication
by prolonging the G2 phase. In addition to inducing apoptosis
in vitro [50,51], Vpr exerts anti-tumor effects in vivo; this latter ef-
fect is seen in immunocompetent mice but not in nude or SCID
mice, suggesting modulation of the immune response rather than
a direct anti-proliferative/apoptotic action [52]. One obvious expla-
nation for the multiple effects of Vpr might be linked to its multiple
intracellular localizations. It would be particularly interesting to
compare the processes controlling the localization of p13 and
Vpr in mitochondria vs. the nucleus and determine if their effects
on cell viability require nuclear targeting or result from mitochon-
drial-nuclear ‘‘retrograde signalling” [53].
8. Concluding remarks and future directions
Experimental data collected so far indicate that p13 mediates a
complex chain of alterations that starts with mitochondrial K+ in-
ﬂux accompanied by an increase in respiratory chain activity and
that can lead to enhanced production of ROS, PTP sensitization
and cell death. The effects of p13 in cells reinforce the emerging
concept that manipulation of mitochondrial function is a key point
of convergence in tumor virus replication strategies.
One of the key questions that should be addressed by future
studies is the molecular mechanism underlying p13’s effects on
K+ permeability, i.e. whether p13 inﬂuences the activity of endog-
enous K+ channels or forms a channel itself. The latter possibility is
suggested by results of biochemical studies described in Ref. [6]
and by structural analogies of p13 with viroporins. To this end bio-
physical experiments in artiﬁcial phospholipid membranes should
provide useful information. Furthermore, the structure of the pro-
tein in the context of mitochondrial membranes should be tested
by NMR and/or crystallographic analyses, which should also con-
tribute to the understanding of the topology of the protein in the
membrane and its intermolecular interactions. Another point that
deserves further studies is the link between the K+ short circuit in
mitochondria and the increase in ROS production, a ﬁnding that
appears to contrast with studies demonstrating that depolarization
induced by protonophores results in reduced ROS production. In
the context of the viral life cycle, p13 might be important in con-
trolling the turnover and tumor transformation of infected cells,
a possibility that could be tested by comparing the replication
and pathogenic properties of wild-type vs. p13-knock-out HTLV-
1 molecular clones in an appropriate animal model.
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